Abstract Library

#314 Clinical Effect of Temozolomide-Based Chemotherapy in Poorly Differentiated Endocrine Carcinoma (PDEC) after Progression on First-Line Chemotherapy

Introduction: Patients with metastatic PDEC usually have a short survival. After first-line palliative chemotherapy, there are no established second-line treatments. Temozolomide has shown effect in other NETs.

Conference: 8th Annual ENETSConcerence (2011)

Presenting Author:

Authors: Welin S, Sorby H, Sebjornsen S, Knappskog S, Busch C,

Keywords: chemotherapy, neuroendocrine cancer, PDEC, second-line, temozolomide,

#100 Mammalian target of rapamycin (mTOR) expression analysis and therapeutic approach in lung and gastroenteropancreatic poorly differentiated endocrine carcinoma (PDEC)

Introduction: PDEC clinically include gastroenteropancreatic PDEC, small cell lung cancer (SCLC) and large cell neuroendocrine carcinoma (LCNEC). These tumors are clinically similar and aggressive and they are usually treated with platinum compounds. mTOR signalling pathway has emerged as a promising target for well-differentiated endocrine carcinoma therapy. Because of varying behavior, PDEC are usually excluded from clinical trials employing the mTOR inhibitor RAD001.

Conference: 7th Annual ENETSConcerence (2010)

Presenting Author:

Authors: Catena L, Milione M, Pusceddu S, Ducceschi M, Avarino M,

Keywords: poorly differentiated endocrine carcinoma, mTOR, RAD001,

#41 Immunohisochemical evaluation of EMT regulators, E- and N-cadherin in neuroendocrine Tumors of the Gastro-Entero-Pancreativ system

Introduction: Local tumor invasion represents the first step of the metastatic cascade of carcinomas, and requires changes in cell adhesion and migration properties of tumor cells. This biologic process is known as epithelial-mesenchymal transition (EMT). One key biochemical change associated with EMT is the loss of E-cadherin expression promoted by specific transcriptional repressors such as Snail, Slug, and Twist. Overexpression of EMT inducers increases other factors, such as FoxC2, although its role in EMT is poorly understood. Neuroendocrine tumors (NETs) of the gastroenteropancreatic (GEP) system, originated from the diffuse endocrine system, represent a heterogeneous group of tumors. Their prevalence has increased substantially over the past three decades, without substantial improvements in their clinical management, and their variable clinical course cannot be predicted by common clinicopathological parameters. Thus, new prognostic markers are urgently needed.

Conference: 7th Annual ENETSConcerence (2010)

Presenting Author:

Authors: GALVÁN J, GONZÁLEZ-MEANA M, FOLGUERAS M, ASTUDILLO A,

Keywords: gastroenteropancreatic neuroendocrine tumors, Twist, FoxC2, N-cadherin, E-cadherin, EMT,